February 7, 2024 Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
February 5, 2024 Achievement of the second milestone under license agreement with Exelixis Inc.
Read More
February 5, 2024 Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
January 31, 2024 Dosing of the first patient in the RIVER-81 Phase II study of RVU120 in combination with venetoclax
Read More
January 31, 2024 Registration of series K subscription warrants of the Company with the National Depository for Securities
Read More
January 18, 2024 Publication dates for periodic reports in 2024
Read More
January 18, 2024 Take-up of series K subscription warrants by the European Investment Bank
Read More
January 3, 2024 Resignation of a member of the Company’s Supervisory Board from his position
Read More
Posts navigation
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Ok Privacy policy 
